AUTL
Price
$1.51
Change
-$0.06 (-3.82%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
417.82M
27 days until earnings call
ELEV
Price
$0.26
Change
-$0.00 (-0.00%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
15.31M
27 days until earnings call
Ad is loading...

AUTL vs ELEV

Header iconAUTL vs ELEV Comparison
Open Charts AUTL vs ELEVBanner chart's image
Autolus Therapeutics
Price$1.51
Change-$0.06 (-3.82%)
Volume$32.59K
Capitalization417.82M
Elevation Oncology
Price$0.26
Change-$0.00 (-0.00%)
Volume$79.37K
Capitalization15.31M
AUTL vs ELEV Comparison Chart
Loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ELEV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUTL vs. ELEV commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUTL is a Buy and ELEV is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (AUTL: $1.51 vs. ELEV: $0.26)
Brand notoriety: AUTL and ELEV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUTL: 136% vs. ELEV: 77%
Market capitalization -- AUTL: $417.82M vs. ELEV: $15.31M
AUTL [@Biotechnology] is valued at $417.82M. ELEV’s [@Biotechnology] market capitalization is $15.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUTL’s FA Score shows that 0 FA rating(s) are green whileELEV’s FA Score has 1 green FA rating(s).

  • AUTL’s FA Score: 0 green, 5 red.
  • ELEV’s FA Score: 1 green, 4 red.
According to our system of comparison, both AUTL and ELEV are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUTL’s TA Score shows that 4 TA indicator(s) are bullish while ELEV’s TA Score has 4 bullish TA indicator(s).

  • AUTL’s TA Score: 4 bullish, 4 bearish.
  • ELEV’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both AUTL and ELEV are a good buy in the short-term.

Price Growth

AUTL (@Biotechnology) experienced а -8.48% price change this week, while ELEV (@Biotechnology) price change was -0.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

AUTL is expected to report earnings on May 01, 2025.

ELEV is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUTL($418M) has a higher market cap than ELEV($15.3M). AUTL YTD gains are higher at: -33.191 vs. ELEV (-53.431). ELEV has higher annual earnings (EBITDA): -40.42M vs. AUTL (-192.51M). AUTL has more cash in the bank: 657M vs. ELEV (93.2M). ELEV has less debt than AUTL: ELEV (31.1M) vs AUTL (52.2M). AUTL has higher revenues than ELEV: AUTL (10.1M) vs ELEV (0).
AUTLELEVAUTL / ELEV
Capitalization418M15.3M2,732%
EBITDA-192.51M-40.42M476%
Gain YTD-33.191-53.43162%
P/E RatioN/AN/A-
Revenue10.1M0-
Total Cash657M93.2M705%
Total Debt52.2M31.1M168%
FUNDAMENTALS RATINGS
AUTL: Fundamental Ratings
AUTL
OUTLOOK RATING
1..100
13
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
93
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AUTLELEV
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 7 days ago
84%
Bullish Trend 23 days ago
87%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ELEV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PLXS130.052.63
+2.06%
Plexus Corp
CHMG47.500.55
+1.17%
Chemung Financial Corp
WPM77.660.83
+1.08%
Wheaton Precious Metals Corp
BRKL10.960.08
+0.74%
Brookline Bancorp
MEIP2.15N/A
N/A
MEI Pharma

AUTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with RCKT. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUTL
1D Price
Change %
AUTL100%
+11.35%
RCKT - AUTL
41%
Loosely correlated
+8.43%
CRSP - AUTL
41%
Loosely correlated
+3.17%
XENE - AUTL
39%
Loosely correlated
+2.68%
DNLI - AUTL
39%
Loosely correlated
+11.80%
OCUL - AUTL
38%
Loosely correlated
+12.23%
More

ELEV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELEV has been loosely correlated with TBPH. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ELEV jumps, then TBPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELEV
1D Price
Change %
ELEV100%
+5.86%
TBPH - ELEV
42%
Loosely correlated
-0.11%
ADAP - ELEV
32%
Poorly correlated
+22.00%
BOLT - ELEV
31%
Poorly correlated
+4.70%
AUTL - ELEV
30%
Poorly correlated
+11.35%
CLDX - ELEV
27%
Poorly correlated
+3.15%
More